Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit

Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease Progression

Release Date: November 30, 2017
Expiration Date: November 30, 2018
Media: Internet - based


Activity Overview

The management of patients with advanced non-small cell lung cancer (NSCLC) who have progressed following prior-platinum-based therapies represents an important educational need among practitioners who care for patients with lung cancer. Although our improved understanding of actionable tumor characteristics has assisted to inform clinical decision-making concerning the use of certain targeted agents, treatment selection for patients who have progressed but who do not have activating mutations is more complex. Clinical status and biomarker information may be used to inform therapeutic selection, but it is also important that practitioners understand results from key trials that have been conducted in patients who have progressed on or after platinum-based approaches. Current treatment options in this regard include immune checkpoint inhibitors, single agent chemotherapy, ramucirumab plus docetaxel, and EGFR tyrosine-kinase inhibitors.

This is an area in lung cancer treatment for which there have been multiple therapeutic developments in recent years. As new biomarkers and patient characteristics continue to emerge that assist clinicians to predict responsiveness to particular approaches, practitioners will need updates that allow them optimize outcomes in these most difficult-to-treat settings of lung cancer management. Education in this regard should focus on the evidence that informs therapeutic selection in post-platinum treated relapsed advanced NSCLC, circumstances that should guide switching of therapies, and methods to proactively manage treatment-related adverse events.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit

CME/CE Activity Table of Contents

  • A Patient With Chemotherapy-Pretreated, Nonsquamous NSCLC
  • A Patient With Chemotherapy-Pretreated, Squamous NSCLC
  • A Patient With Immunotherapy-Pretreated, Squamous NSCLC
  • A Patient With EGFR TKI and Chemotherapy-Pretreated NSCLC

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This online activity is directed toward oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Assess testing methods that should be applied to inform clinical decision-making for patients with advanced NSCLC who have progressed following platinum-based chemotherapy
  • Describe landmark clinical trials that have evaluated patients with advanced NSCLC who have progressed on platinum-based therapeutic approaches
  • Explain strategies to proactively address treatment-related adverse events in patients with advanced NSCLC
  • Construct an algorithm based on clinical and biomarker information for the management of patients who have progressed following platinum-based chemotherapy in either front-line treatment or following front-line immunotherapy

Faculty, Staff, and Planners' Disclosures


Edward Garon, M.D., MS
Associate Professor, Department of Medicine; Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure: AstraZeneca, Boehringer-Ingelheim, BMS, Genentech, Eli Lilly, Merck. Mirati, Novartis and Pfizer

Benjamin P. Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosure: Celgene, Astra-Zeneca, Eli-Lilly, Genentech, Pfizer, Merck

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By